Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 15/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3165162 | 1.00 | PTGS1 (0.45) | PTGS1PTGS2F10MAOAMAOB | |
| SCHEMBL4627759 | 0.82 | PTGS1 (0.47) | PTGS1PTGS2F10MAOAMAOB | |
| SCHEMBL686180 | 0.82 | PTGS1 (0.44) | PTGS1PTGS2F10MAOAMAOB | |
| SCHEMBL4627757 | 0.82 | PTGS1 (0.47) | PTGS1PTGS2F10MAOAMAOB | |
| SCHEMBL5646039 | 0.78 | PTGS1 (0.46) | PTGS1PTGS2F10MEN1KMT2A | |
| SCHEMBL5646036 | 0.78 | PTGS1 (0.46) | PTGS1PTGS2F10MEN1KMT2A | |
| SCHEMBL4939340 | 0.78 | MEN1 (0.37) | F10MEN1KMT2A | |
| SCHEMBL4939345 | 0.78 | MEN1 (0.37) | F10MEN1KMT2A | |
| SCHEMBL13991504 | 0.78 | PTGS1 (0.44) | PTGS1PTGS2F10F2KLKB1 | |
| SCHEMBL4061257 | 0.75 | PTGS1 (0.43) | PTGS1PTGS2MAOAMAOBF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115874239-B | Electroplating process | 温州市金牛电镀有限公司 | 2025-04-08 | — | — | CN | claimed |
| CN-115874239-A | Electroplating process | 温州市金牛电镀有限公司 | 2023-03-31 | — | — | CN | claimed |
| CN-115874239-B | Electroplating process | 温州市金牛电镀有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-115874239-A | Electroplating process | 温州市金牛电镀有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-7645338-B2 | Crystalline derivatives of (E)-2-(5-chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide | GLAXO GROUP LIMITED (GB) | 2010-01-12 | — | — | US | disclosed |
| US-7612075-B2 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090170844-A1 | Spiro Tetracyclic Compound | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-7517879-B2 | Pyrrolidine derivatives as factor Xa inhibitors | GLAXO GROUP LIMITED (GB) | 2009-04-14 | — | — | US | disclosed |
| EP-2020411-A1 | SPIRO TETRACYCLIC COMPOUND | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-02-04 | — | — | EP | disclosed |
| US-7482374-B2 | Pyrrolidine-2-ones as Factor Xa inhibitors | GLAXO GROUP LIMITED (GB) | 2009-01-27 | — | — | US | disclosed |
| US-20020013310-A1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2002-01-31 | — | — | US | disclosed |
| EP-1086099-A4 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARM PROD INC (US) | 2002-01-02 | — | — | EP | disclosed |
| US-6281227-B1 | INHIBITORS OF THE ACTIVITY OF FACTOR XA. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-08-28 | — | — | US | disclosed |
| EP-1086099-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-2001007436-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| EP-1051176-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-2000032590-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-1999062904-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| WO-1999037304-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170844-A1 | Spiro Tetracyclic Compound | KCNH1, TFPI, KCNN2 | PTGS1 1736/4885PTGS2 2140/4885F10 127/4885 |
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | TFPI, SERPINC1, SERPINE1 | PTGS1 741/4885PTGS2 1284/4885F10 11/4885 |
| US-20020013310-A1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | STS, ARSA, F12 | PTGS1 695/4885PTGS2 1077/4885F10 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.